Du Mengyang, Yue Jiang, Qi Yicheng, He Shengyun, Lu Xiaobing, Yang Minglan, Wang Lihua, Lu Qing, Ma Jing
Department of Endocrinology and Metabolism, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No.160 Pujian Road, Shanghai, 200127, China.
Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No.160 Pujian Road, Shanghai, 200127, China.
Diabetol Metab Syndr. 2024 Dec 20;16(1):307. doi: 10.1186/s13098-024-01540-4.
To observe the effects of liraglutide on abdominal fat distribution in Chinese subjects with obesity in 12 weeks, and further to explore the correlation between abdominal fat content and glucose metabolism after monotherapy.
This study recruited 71 obese subjects. All the subjects have received liraglutide monotherapy (0.6 mg-1.8 mg/d) for 12 weeks. Clinical assessment, laboratory assays and magnetic resonance imaging (MRI) examination were accessed at baseline and after 12 weeks treatment. MRI was applied to measure abdominal fat distribution, calculated by proton-density fat fraction (PDFF).
After 12 weeks of liraglutide monotherapy, body weight in the obese participants decreased significantly (P < 0.001). Fasting blood glucose (FBG) levels, 2 h post-load blood glucose (2hPBG) levels, and glycosylated hemoglobin (HbA1c) were remarkably improved after liraglutide monotherapy (all P < 0.001). Subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) were significantly reduced after liraglutide monotheraphy (both P < 0.001). There was a notable reduction in liver fat content (LFC) after liraglutide monotherapy (P < 0.001). In the further analysis, LFC was greater in obese subjects with impaired glucose regulation (IGR) at baseline compared to those with normal glucose tolerance (NGT) (P = 0.002). The LFC reduction in IGR group was significantly greater than those in NGT group after liraglutide treatment (P < 0.001). Pearson correlation analysis showed that reduction of LFC was significantly correlated with improvement of FBG (r = 0.587, P < 0.001) and HbA1c (r = 0.607, P < 0.001) in obese patients.
LFC was significantly reduced after liraglutide monotherapy for 12 weeks in subjects with obesity. The LFC reduction is likely to be associated with IGR remission in obese subjects.
观察利拉鲁肽对中国肥胖受试者腹部脂肪分布的影响，并进一步探讨单药治疗后腹部脂肪含量与糖代谢之间的相关性。
本研究招募了71名肥胖受试者。所有受试者均接受利拉鲁肽单药治疗（0.6毫克至1.8毫克/天），为期12周。在基线和治疗12周后进行临床评估、实验室检测和磁共振成像（MRI）检查。采用MRI测量腹部脂肪分布，通过质子密度脂肪分数（PDFF）计算。
利拉鲁肽单药治疗12周后，肥胖参与者的体重显著下降（P<0.001）。利拉鲁肽单药治疗后，空腹血糖（FBG）水平、餐后2小时血糖（2hPBG）水平和糖化血红蛋白（HbA1c）均显著改善（均P<0.001）。利拉鲁肽单药治疗后，皮下脂肪组织（SAT）和内脏脂肪组织（VAT）均显著减少（均P<0.001）。利拉鲁肽单药治疗后，肝脏脂肪含量（LFC）显著降低（P<0.001）。在进一步分析中，与葡萄糖耐量正常（NGT）的肥胖受试者相比，基线时葡萄糖调节受损（IGR）的肥胖受试者的LFC更高（P=0.002）。利拉鲁肽治疗后，IGR组的LFC降低幅度显著大于NGT组（P<0.001）。Pearson相关性分析表明，肥胖患者LFC的降低与FBG的改善（r=0.587，P<0.001）和HbA1c的改善（r=0.607，P<0.001）显著相关。
肥胖受试者接受利拉鲁肽单药治疗12周后，LFC显著降低。LFC的降低可能与肥胖受试者IGR的缓解有关。
